Research programme: Antibacterials - Roche/Venatorx Pharmaceuticals
Latest Information Update: 30 May 2024
At a glance
- Originator Roche; VenatoRx Pharmaceuticals
- Class Antibacterials; Small molecules
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 30 May 2024 Preclinical trials in Gram-negative infections in USA (unspecified route), before May 2024 (VenatoRx Pharmaceuticals website, May 2024)
- 01 Nov 2021 Venatorx Pharmaceuticals and Roche agree to co-develop antibacterials
- 01 Nov 2021 Early research in Gram negative infections in USA (unspecified route)